Table 7.
Glucagon and related peptide analogues at preclinical stage for T2DM.
| Peptide Name | AA Sequence | Target Receptor | Reference |
|---|---|---|---|
| Native glucagon | HSQGTFTSDYSKYLDSRRAQDFVQWLMNT | CGCR | (10) |
| N-Acetyl-glucagon | Ac-HSQGTFTSDYSKYLDSRRAQDFVQWLMNT | GCGR | (365) |
| (D-Ser2)glucagon | HDSQGTFTSDYSKYLDSRRAQDFVQWLMNT | GCGR/GLP-1R | (365) |
| (D-Ser2)glucagon-exe | HDSQGTFTSDYSKYLDSRRAQDFVQWLMNTPSSGAPPPS | GCGR/GLP-1R | (365) |
| Dogfish Glucagon | HSEGTFTSDYSKYMDNRRAKDFVQWLMSTKRNG | GCGR/GLP-1R | (366, 367) |
| (D-Ala2)dogfish glucagon | HDAEGTFTSDYSKYMDNRRAKDFVQWLMSTKRNG | GCGR/GLP-1R | (366, 367) |
| (D-Ala2)dogfish glucagon-exendin-4(31-39) | HDAEGTFTSDYSKYMDNRRAKDFVQWLMSTKRNGPSSGAPPPS | GCGR/GLP-1R | (366, 367) |
| (D-Ala2)dogfish glucagon-Lys30-γ-glutamyl-PAL | HDAEGTFTSDYSKYMDNRRAKDFVQWLMSTK(*PAL)RNG | GCGR/GLP-1R | (366, 367) |
| Paddlefish glucagon | HSQGMFTNDYSKYLEEKRAKEFVEWLKNGKS | GCGR/GLP-1R | (248) |
Amino acid sequences are provided in their single-letter abbreviation format. Modifications from native sequences are highlighted by red lettering. The receptor targets for each molecule are provided. A “D” prefix before a residue indicates inclusion of the enantiomer for the naturally-occurring L form of the residue. “Ac” represents an N-terminal acetylation. “mPEG” indicates mini-polyethylene glycol addition. “PAL” indicates the addition of a palmitic fatty acid chain.